CSIMarket
 
Atai Life Sciences N v   (ATAI)
Other Ticker:  
 
 
Price: $1.7700 $0.09 5.357%
Day's High: $1.8 Week Perf: -12.38 %
Day's Low: $ 1.70 30 Day Perf: 0.00
Volume (M): 941 52 Wk High: $ 2.39
Volume (M$): $ 1,666 52 Wk Avg: $1.64
Open: $1.70 52 Wk Low: $1.03



 Market Capitalization (Millions $) 314
 Shares Outstanding (Millions) 178
 Employees -
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -71
 Cash Flow (TTM) (Millions $) -66
 Capital Exp. (TTM) (Millions $) 1

Atai Life Sciences N V
Atai Life Sciences N.V. is a global biotech company that specializes in developing transformative therapies for mental health disorders. The company focuses on discovering and developing innovative treatments for conditions such as depression, anxiety, addiction, and other related disorders. They strive to address the unmet needs in mental health by utilizing cutting-edge research, technology, and strategic partnerships. Atai Life Sciences aims to improve the way mental health disorders are diagnosed, treated, and understood to ultimately enhance the quality of life for individuals suffering from these conditions.


   Company Address: ATAI Life Sciences N.V. Berlin 0
   Company Phone Number: 2153 9035   Stock Exchange / Ticker: NASDAQ ATAI
   ATAI is expected to report next financial results on March 23, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Partnership

atai Life Sciences Partners with Beckley Psytech to Revolutionize Mental Health Treatment through Short-Duration Psychedelics

Published Thu, Jan 4 2024 12:00 PM UTC

The collaboration between atai Life Sciences and Beckley Psytech is aimed at accelerating the clinical development of short-duration psychedelics. These substances have shown promise in rapidly alleviating symptoms of various mental health disorders, including depression, anxiety, PTSD, and addiction.By investing in Beckley Psytech, atai Life Sciences is positioning itself a...

Clinical Study

Positive Results from EMP-01 Phase 1 Study: A Promising Breakthrough in Mental Health Treatment

Published Tue, Jan 2 2024 1:01 PM UTC

atai Life Sciences, a renowned clinical-stage biopharmaceutical company dedicated to revolutionizing mental health disorder treatments, has recently disclosed encouraging findings from their Phase 1 study involving EMP-01 (R-MDMA). This orally administered drug, derived from the well-known MDMA (3,4-methylenedioxy-methamphetamine), has demonstrated significant potential in a...

Atai Life Sciences N V

Leading Pharmaceutical Company Soars: Revenues Skyrocket while EPS Shows Remarkable Improvement in Q3 2023



ATAI Life Sciences N.V., a major pharmaceutical preparations company, has recently released its financial results for the July to September 30, 2023 period. The company showcased an impressive revenue rise of 262.5% year on year to $0.09 million. More notably, ATAIs achieved a surplus and presented earnings per share (EPS) at $0.25, marking a significant improvement compared to the preceding quarter. This article will delve into the facts and interpret the financial results while pondering the potential implications for the company's future.
Revenue Surge and EPS Advancement:
ATAI Life Sciences recorded remarkable revenue growth, with a surge of 262.5% year on year. This robust performance demonstrates the company's ability to capitalize on market opportunities and execute its business strategies effectively. Despite a 49.419% decline in revenue compared to the preceding quarter, ATAIs' revenue turnaround highlights their agility and resilience to navigate fluctuations in the pharmaceutical industry.

Atai Life Sciences N V

Atai Life Sciences N.V. Defies Industry Trend with Revenue Surge in Q2 2023 Earnings Season

Atai Life Sciences N.V. Reports Soft Revenue Growth in Q2 2023 Earnings Season
During the second quarter of the 2023 earnings season, Atai Life Sciences N.V. faced a net loss of $-0.21 per share. This was an improvement from the previous year's figure of $-0.24 per share. Comparatively, the company had reported a net loss of $-0.21 per share in the previous reporting season. The Revenue for the quarter showed a slight increase of 1.176% to $0.17 million, remaining consistent with the same reporting period the previous year. However, the sequential Revenue surged significantly by 364.865% from $0.04 million.
Atai Life Sciences N.V., a major player in the Major Pharmaceutical Preparations industry, defied the trends observed in the sector. While most other companies in the industry experienced revenue contractions during the same period, Atai Life Sciences N.V. showcased top-line growth.

Atai Life Sciences N V

1. Revised headline: Atai Life Sciences N V Reports Positive Revenue of $0.037 Million in First Quarter 20232. Subtitle: Advancing Psychedelic Drug Development for Mental Health Treatment: Atai Life Sciences N V Shows Promising Financial Progress

Atai Life Sciences N V, the biopharmaceutical company focused on developing psychedelic drugs for mental health treatment, has announced its financial results for the first quarter of the 2023 earnings season. The company reported $0.037 million in revenue, which is a positive sign for investors after the company's struggles in the past.
However, the company also reported a net shortfall of $-34.354 million in the first quarter, which is better than the deficit of $-37.558 million in the same period a year ago. This improvement in their financial performance is a welcome development for Atai Life Sciences N V investors.
Atai Life Sciences N V's management team has been working hard to develop and advance its pipeline of psychedelic drugs for mental health treatment. Psychedelics have been gaining increasing attention in recent years due to their potential to treat depression, anxiety, and other mental health disorders. Atai Life Sciences N V has been leading the charge in this field by investing in and developing promising drugs.






 

Atai Life Sciences N V's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com